ArticleThe American journal of pathology2012
Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function.
Article in The American journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Butyrate-Producing Mixed Probiotics Alleviate MRSA-Induced Acute Lung Injury in Mice by Promoting M2 Macrophage Polarization.Probiotics and antimicrobial proteins · 2026Article
- Review
- SARS-CoV-2 reinfection and implications for vaccine development.Human vaccines & immunotherapeutics · 2020Review
- Article
- Novel protective mechanism for interleukin-33 at the mucosal barrier during influenza-associated bacterial superinfection.Mucosal immunology · 2018Article
- IFNAR2 Is Required for Anti-influenza Immunity and Alters Susceptibility to Post-influenza Bacterial Superinfections.Frontiers in immunology · 2018Article
- Article
- VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation.Scientific reports · 2017Article
- Article
- In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer.Nature nanotechnology · 2016Article
- Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease.Infection and immunity · 2015Review
- A Learner-led, Discussion-based Elective on Emerging Infectious Disease.American journal of pharmaceutical education · 2015Article
- Regulation of IFN-γ by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia.European journal of immunology · 2014Article
- CD11c⁺ cells primed with unrelated antigens facilitate an accelerated immune response to influenza virus in mice.European journal of immunology · 2014Article
- Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung.Nanomedicine (London, England) · 2014Review
- Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.ACS nano · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 2 countries.
Funding
Abstract
The importance of the priming of the lung environment by past infections is being increasingly recognized. Exposure to any given antigen can either improve or worsen the outcome of subsequent lung infections, depending on the immunological history of the host. Thus, an ability to impart transient alterations in the lung environment in anticipation of future insult could provide an important novel therapy for emerging infectious diseases. In this study, we show that nasal administration of virus-like particles (VLPs) before, or immediately after, lethal challenge with methicillin-resistant Staphylococcus aureus (MRSA) of mice i) ensures complete recovery from lung infection and near absolute clearance of bacteria within 12 hours of challenge, ii) reduces host response-induced lung tissue damage, iii) promotes recruitment and efficient bacterial clearance by neutrophils and CD11c(+) cells, and iv) protects macrophages from MRSA-induced necrosis. VLP-mediated protection against MRSA relied on innate immunity. Complete recovery occurred in VLP-dosed mice with severe combined immunodeficiency, but not in wild-type mice depleted of either Ly6G(+) or CD11c(+) cells. Early IL-13 production associated with VLP-induced CD11c(+) cells was essential for VLP-induced protection. These results indicate that VLP-induced alteration of the lung environment protects the host from lethal MRSA pneumonia by enhancing phagocyte recruitment and killing and by reducing inflammation-induced tissue damage via IL-13-dependent mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.